Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 1,438 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 1,438 shares of Zai Lab stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total value of $50,933.96. Following the transaction, the chief financial officer directly owned 16,720 shares of the company’s stock, valued at approximately $592,222.40. The trade was a 7.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Yajing Chen also recently made the following trade(s):

• On Friday, August 8th, Yajing Chen sold 4,096 shares of Zai Lab stock. The shares were sold at an average price of $34.01, for a total value of $139,304.96.
• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The shares were sold at an average price of $36.13, for a total value of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The shares were sold at an average price of $30.00, for a total value of $288,540.00.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB opened at $35.69 on Tuesday. Zai Lab Limited Unsponsored ADR has a twelve month low of $16.56 and a twelve month high of $44.34. The firm has a market cap of $3.96 billion, a PE ratio of -17.50 and a beta of 1.03. The business has a fifty day moving average of $36.63 and a 200-day moving average of $33.64.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting analysts’ consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. On average, analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZLAB shares. Leerink Partners set a $75.00 price objective on Zai Lab and gave the company an “outperform” rating in a report on Monday, June 30th. Wall Street Zen lowered Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Finally, Citigroup restated a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and a consensus price target of $57.22.

Institutional Trading of Zai Lab

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Zai Lab in the first quarter worth about $1,073,000. MPM Bioimpact LLC increased its position in Zai Lab by 4.2% in the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company’s stock worth $30,128,000 after purchasing an additional 33,659 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Zai Lab in the first quarter worth about $12,649,000. Cubist Systematic Strategies LLC increased its position in Zai Lab by 29.0% in the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company’s stock worth $3,384,000 after purchasing an additional 21,026 shares during the period. Finally, Royal Bank of Canada increased its position in Zai Lab by 214.3% in the first quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock worth $498,000 after purchasing an additional 9,390 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.